Valneva to Present and Host Investor Meetings at U.S. and European Healthcare Conferences

Valneva's senior management will present and participate in investor conferences in the US and Europe. The company will discuss its key value drivers and upcoming catalysts, including the Phase 3 trial outcomes for VLA15, its Lyme disease vaccine candidate partnered with Pfizer. Valneva expects Pfizer to launch the vaccine in the second half of 2027 if successful. Institutional investors can request meetings with Valneva management at the conferences.